H.C. Wainwright analyst Yi Chen lowered the firm’s price target on IceCure Medical (ICCM) to $2 from $2.50 and keeps a Buy rating on the shares post the Q2 report. The firm’s projected shares outstanding in 12 months increased meaningfully as a result of IceCure’s recent rights offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- Buy Rating for Icecure Medical: Strategic Positioning and Promising Advancements in Breast Cancer Treatment
- IceCure Medical Reports 2025 First Half Results
- IceCure Medical Reports First Half 2025 Financial Results
- Icecure Medical Ltd. (ICCM) Q2 Earnings Cheat Sheet
- IceCure Medical Successfully Closes Oversubscribed Rights Offering